How did Chinese listed companies perform in the first half of the year? As of June 30, 2022, a total of 8,392 Chinese listed companies have been listed on 16 major exchanges in the world, including Shanghai, Shenzhen, Beijing, Hong Kong and New York.

Meridian Bioscience announced on Thursday that it has entered into an agreement to be acquired by a newly formed affiliate of Korean diagnostic company SD Biosensor and investment firm SJL Partners for about $1.53 billion.

MirXes, a Singapore-based RNA testing firm, said on Thursday it has signed a memorandum of understanding with several Singapore universities and hospitals to launch a study of circulating microRNA and DNA methylation biomarkers for multi-cancer early detection.

Recently, Peng Yang, Vice President of Danaher Global Yang Peng visited Suzhou BioLihe. The two parties had an in-depth communication on the Danaher Business System (DBS) and BioLihe¡¯s production and operation.

Guardant Health and Chinese clinical laboratory firm Adicon said on Wednesday that they have signed a strategic partnership under which Adicon has licensed Guardant's tissue and blood-based genomic cancer assays

BioM¨¦rieux, Boehringer Ingelheim, and Evotec announced on Wednesday the creation of a joint venture to develop and commercialize new antimicrobials and diagnostics.

Bio-Techne said on Wednesday that it has recently received CE marking and launched in Europe its assay for human papillomavirus for use in patients with head and neck cancer.

Recently, Wuhan YZY Biopharma Co., Ltd completed a 200 million CNY Pre-C round of financing. This round of financing was completed by the joint investment of Wuhan Hi-Tech, Hubei Science Technology Investment and Optics Valley Financial Holding Group.

The FDA cautioned in late 2021 after the omicron variant emerged that antigen tests may have reduced sensitivity, meaning they correctly identify fewer people with COVID-19. Data have continued to accumulate that the tests are not as sensitive to the newer variants of the virus, Stenzel said.

Forgetfulness and memory loss can be a normal part of aging, but can also signify the onset of dementia, one of the major causes of disability and dependency in old age.

Although Covid-19 is not over yet, the market conditions of nucleic acid and antigen detection reagents are rapidly cooling down, and even "cliff-like" subsidence.

Despite significant and stunning advances in vaccine technology, the COVID-19 global pandemic is not over. A key challenge in limiting the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is identifying infected individuals.

New research led by Edith Cowan University has made an important discovery that could lead to more effective treatments for the world¡¯s 262 million asthma sufferers

On July 2, 2022, Mgi Tech Co., Ltd and Guangzhou Burning Rock Biotech Co., Ltd. officially reached a strategic cooperation.

FDA issued a recommendation on June 30, 2022 to COVID-19 vaccine manufacturers that indicated that they should include an Omicron subvariant BA.4/5 component in their vaccines.

PreventionGenetics said Thursday that it has been granted marketing authorization for its POMC/PCSK1/LEPR companion diagnostic as a Class II device by the US Food and Drug Administration.

Recently, the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) announced the second batch of Certificate of Export Commodity Brand list recommended by the chamber of Commerce for medical insurance in 2022.

Becton Dickinson has obtained the CE-IVD mark on a combined panel assay to detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus. The assay runs on the firm's BD Max instrument and is now available in countries that recognize the CE mark, the firm said on Thursday.

Visby Medical said on Wednesday that it has added $35 million to its Series E financing round, bringing its total proceeds from the round to more than $135 million.

On June 28, the National Health Commission of the PRC released the "COVID-19 Prevention and Control Plan (Ninth Edition)". Compared with the eighth edition, the following revisions were made: